UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR For the transition period from to Commission file number: 001-37465 Seres Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 27-4326290 (State or other jurisdiction of incorporation or organization) 200 Sidney Street - 4th Floor Cambridge, MA 02139 ...

Seres Therapeutics Overview Eric Shaff, President and Chief Executive Officer Cowen Health Care Conference March 2, 2020 Forward looking statements Some of the statements in this presentation constitute "forward looking statements" under the Private Securities Litigation Reform Act of 1995, including, but not limited to, our development plans, the promise and potential impact of any of our microbiome therapeutics or clinical trial data, the ability of our clinical trials to support approval, the timing of c ...

Seres Therapeutics, Inc. (NASDAQ:MCRB) Q4 2019 Results Earnings Conference Call March 2, 2020 8:30 AM ET Company Participants Carlo Tanzi - Investor Relations Eric Shaff - President and Chief Executive Officer Matt Henn - Chief Scientific Officer Conference Call Participants Pam Barrett - Cowen Mark Breidenbach - Oppenheimer John Newman - Canaccord Operator Ladies and gentlemen, thank you for standing by and welcome to the Fourth Quarter Seres Therapeutics Earnings Conference Call. At this time, all partici ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37465 Seres Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 27-4326290 (State or Other Jurisdiction ...

| --- | --- | --- | --- | |-------|-----------------------------------|-------|-----------------------------| | | | | | | | | | | | | | | | | | | | Seres Therapeutics Overview | | | Stifel 2019 Healthcare Conference | | | | | November 19, 2019 | | | | | | | | | | | | | Forward looking statements | --- | --- | |----------------------------------------------------------------------------------------------------------------------------------------------------|-------------------| | | | | included herein repres ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37465 Seres Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 27-4326290 (State or other j ...

Seres Therapeutics, Inc. (NASDAQ:MCRB) Q3 2019 Earnings Conference Call November 5, 2019 8:30 AM ET Company Participants Carlo Tanzi - Investor Relations Eric Shaff - President and Chief Executive Officer Matt Henn - Chief Scientific Officer Conference Call Participants Chris Shibutani - Cowen and Company Holly Barra - Goldman Sachs Chris Howerton - Jefferies Vernon Bernardino - H.C. Wainwright Operator Ladies and gentlemen, thank you for standing by and welcome to Q3 2019 Seres Therapeutics Earnings Confer ...

(Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37465 Seres Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 27-4326290 (State or other jurisd ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37465 Seres Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 27-4326290 (State or other juris ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37465 Seres Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 27-4326290 (State or Other Jurisdiction of Incorporation or Organization) 200 Sidney Street – 4th Floor Cambridge, Massachusetts 02139 (Address of Principal Executive Offices) (Zip Code) (IRS Employer Identifica ...